Seres Therapeutics, a leading live biotherapeutics company, announced the receipt of a $50 million installment payment from Nestlé Health Science, related to the previously disclosed sale of its VOWST business. This payment, received as expected, further solidifies Seres’ financial position and provides a clear runway for continued operations into the first quarter of 2026.
